Cytograft currently has ongoing clinical trials in both Europe and South America. Clinical results from Cytograft’s lead product, the Lifeline™ graft for hemodialysis access have been reported in both the New England Journal of Medicine and the Lancet.
Updates will be posted on this website and will also be available on www.clinicaltrials.gov.